Smart MCs is proud to share that our Chief Technology Officer, Dr. Lin Ding, presented at the 15th International NanoMedicine Conference (OzNanoMed 2025), held from 16–18 June at the Pier One Sydney Harbour Hotel in Sydney.

On Tuesday, 17 June at 2:15 PM (AEST), Lin delivered a talk titled

“Redraw Our Roadmap with Customer Voices: The Iterative Path to Commercialisation”

Bridging the Gap Between Innovation and Application

Lin’s presentation focused on the commercialisation of microcarriers — a foundational platform technology for cell therapy, bioprocessing, and regenerative medicine. Drawing on Smart MCs’ real-world experience, he explored how customer feedback shaped the company’s strategy, guiding a critical pivot from research-driven design to market-aligned development.

“We discovered a clear disconnect,” Lin shared, “where academic researchers prioritized novel functionality, but end users emphasized scalability, reproducibility, and cost-efficiency.”

This insight led Smart MCs to reframe its development roadmap and enhance the microcarrier platform to meet commercial and clinical demands.

Real-World Commercialisation for Scientific Impact

The talk highlighted key lessons for researchers and startups working to commercialise biotechnology innovations. Lin emphasized the importance of early stakeholder engagement, continuous market feedback, and cross-sector collaboration.

“Commercialising scientific innovations requires more than just technology. It requires listening,” he said.
“That’s how research transforms into impact.”

Conference Highlights

Smart MCs thanks the OzNanoMed 2025 organizers for creating an inspiring and collaborative space for global leaders in nanomedicine and biotech commercialisation. We were honored to contribute to the conversation and connect with fellow innovators.